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pression or venous stenosis at the thoracic outlet.4,5 There
is continued debate with regard to the operative approach
and appropriate timing of such surgery.4-8
The treatment approach to SAVT at our institution dif-
fers in that surgical decompression of the thoracic outlet is
used relatively infrequently after an episode of SAVT. After
initial thrombolysis, patients have been maintained on anti-
coagulation for 3 months. Routine follow-up imaging stud-
ies were not performed on all patients. At subsequent
reevaluations the decision whether to proceed with thoracic
outlet decompression was based on the severity of the
patients’ symptoms. As a result few of our patients have
undergone surgical decompression of the thoracic outlet for
this condition. The aim of this study was to determine the
functional outcome of patients treated in such a manner.
MATERIAL AND METHODS
All cases of venographically confirmed SAVT treated at
a single tertiary level hospital between 1989 and 1998
were reviewed. Only patients admitted for their first
episode of SAVT were considered eligible. Patients with
secondary SAVT (eg, those with indwelling catheters,
hypercoagulable states, pacemaker wires) were excluded.
Demographic features, presenting symptoms, and initial
treatments were determined by a retrospective review of
hospital charts. 
Venography performed to diagnose SAVT was per-
formed through an ipsilateral brachial vein approach. After
Primary subclavian-axillary vein thrombosis (SAVT) is
a relatively uncommon disorder accounting for about 1%
to 4% of all deep vein thromboses.1 Nonetheless, it is a seri-
ous disorder that affects young, otherwise healthy patients
and has the potential to cause significant long-term mor-
bidity.2 Treatment for this condition has traditionally con-
sisted of anticoagulation, along with arm rest and
elevation. Studies have since then demonstrated that early
thrombolysis can restore venous patency in most patients,
particularly if it is used early after the onset of thrombosis.3
Extrinsic compression of the subclavian vein at the thoracic
outlet is undoubtedly an important factor in the develop-
ment of this condition, and more recent reports advocate
surgical decompression of the thoracic outlet after throm-
bolysis if there is venographic evidence of extrinsic com-
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Purpose: Treatment for primary subclavian-axillary vein thrombosis (SAVT) at our institution consists of thrombolysis
and anticoagulation for 3 months. Thoracic outlet decompression has been performed for a small number of patients.
We wanted to review the functional outcomes of patients treated in such a manner.
Material and Methods: The records of all patients treated for a first episode of SAVT at our hospital over the past 10
years were reviewed. Demographics, comorbidities, method of diagnosis, and treatment for SAVT were recorded. Long-
term follow-up was obtained by chart review and asking patients to complete the DASH (disabilities of the arm, shoul-
der and hand) questionnaire that was developed by the American Academy of Orthopedic Surgeons.
Results: Twenty-eight patients, 20 men and eight women, with a mean age of 36 were treated during the study period.
The median time between onset of symptoms and treatment was 5.5 (range, 1-100) days. All patients had confirma-
tion of the diagnosis by venography. Twenty-five patients received thrombolytic treatment with catheter-directed infu-
sions of urokinase; in the other three patients the vein was chronically occluded. Twelve patients had some degree of
residual stenosis and were treated with percutaneous transluminal angioplasty after thrombolysis. During the study
period two patients underwent decompressive surgery. Twenty-one patients responded to the DASH questionnaire a
mean of 2.9 years (range, 2 months to 8 years) after the episode of SAVT. Six (28%) of 21 patients were completely
symptom free, 13 patients (62%) had DASH scores consistent with mild symptoms, and two patients had more severe
symptoms. Twenty percent (4 of 21) of patients report some difficulty with work.
Conclusions: Thrombolysis, followed by selective thoracic outlet decompression on the basis of the severity of patients’
symptoms can be used as a therapeutic approach to SAVT without undue morbidity. The DASH questionnaire is a use-
ful tool to evaluate results after therapy for SAVT. (J Vasc Surg 2001;33:783-8.)
confirmation of the diagnosis, an attempt at catheter-
directed thrombolysis was made in all cases. If a guide wire
could be passed through the thrombus, an infusion catheter
was positioned, and an initial bolus of thrombolytic was
given with the pulse-spray method. Urokinase was used in
all cases, and the dose of the initial bolus ranged from
100,000 to 1,000,000 units. After the initial bolus, a con-
tinuous infusion of urokinase was begun at rates ranging
from 50,000 to 240,000 units per hour. Interval venograms
were obtained to assess efficacy of treatment, and adminis-
tration of urokinase was discontinued when there was com-
plete lysis or with lack of improvement on serial venograms.
During treatment patients were maintained on heparin with
the goal of keeping partial thromboplastin times at least two
times greater than normal. 
After thrombolysis treatment ended, patients contin-
ued to receive intravenous heparin, and oral anticoagula-
tion with warfarin was begun. Patients were discharged on
warfarin when their international normalized ratio (INR)
was between 2 and 3. If thrombolysis was successful, treat-
ment with warfarin was continued for 3 months after the
initial episode and then stopped. Follow-up imaging stud-
ies such as duplex studies or venography were done at the
discretion of individual surgeons. The decision to proceed
with thoracic outlet decompression was based on the
patient’s symptoms and disability at follow-up visits.
Patients with mild or no symptoms were given no further
treatment.
We attempted to contact all patients for long term fol-
low-up. Those whom we were able to contact were asked
to fill out a questionnaire with regard to their upper
extremity function. A review of individual physicians’
office records was done to supplement follow-up. 
The instrument used to measure burden of symptoms
and functional impairment was the DASH (disabilities of the
arm, shoulder, and hand) questionnaire. This questionnaire
is an outcomes data evaluation tool that was developed by
the American Academy of Orthopedic Surgeons, the
Council of the Musculoskeletal Specialty Societies, and the
Institute for Work and Health to evaluate outcome among
patients with upper extremity disorders.9,10 This question-
naire has been developed relatively recently and is starting to
be used for a variety of upper extremity disorders.10-12
DASH consists of 30 questions pertaining to function and
symptoms of the upper extremity and is scored such that 0
represents no symptoms or impairment at all and 100 repre-
sents complete disability of the extremity and maximal symp-
toms. There are also two four-question modules pertaining
to the subject’s ability to perform his or her favorite sport-
ing or musical activity and one concerning the subject’s abil-
ity to perform at the workplace. These modules are similarly
scored from 0 to 100. Permission was obtained from the
Clinical Research Ethics Board of the University of British
Columbia to perform this study. 
RESULTS
During the study period, 28 patients (20 men and 8
women) were diagnosed with their first episode of primary
SAVT. The mean age of these patients was 36. Twenty-three
of these patients had thrombosis on the side of their domi-
nant hand. Patients were diagnosed a median of 5.5 days
after the onset of symptoms (range, 1-100 days). A history
of recent strenuous activity was noted in 16 of the patients.
Thrombolysis was initiated in 25 of 28 patients. The
three other patients had a chronic occlusion across which
a guide wire could not be passed. Thrombolysis was suc-
cessful in clearing all thrombus in 22 patients; three
patients had some residual thrombus after completion of
thrombolysis. Of the 22 patients with complete clearance
of thrombus, seven patients had completely normal
venograms, and two patients had normal-looking veins
with evidence of extrinsic compression with provocative
maneuvers. Thirteen patients were noted to have intrinsic
venous narrowing, and 12 of these patients underwent
percutaneous transluminal angioplasty (PTA) to 12 mm.
PTA appeared to improve the luminal caliber in six
patients. Two of these patients had no residual stenosis,
and four patients had residual stenoses < 50%. These
results are depicted in Fig 1. No patient was documented
to have rethrombosis while in hospital. No major bleeding
complications were noted in patients receiving thrombol-
ysis. A pulmonary embolus developed in one patient while
in hospital. Before discharge all patients with open veins
began receiving warfarin, which was continued for a min-
imum of 3 months. Of the three patients with chronic
occlusions, two of the three were given anticoagulants for
2 and 3 months. None of these three patients received any
other treatment.
Twenty-four of the 28 patients were seen at initial 
follow-up from 6 to 17 weeks after the episode of SAVT.
Four patients did not return for any follow-up visits.
Follow-up imaging studies have been performed in 11
patients (6 duplex scans and 5 venograms) at a time inter-
val of 3 to 17 months after the episode of SAVT. All of
these patients had patent veins after thrombolysis. Three
patients were found to have occluded subclavian veins on
follow-up, including one patient who had undergone
claviculectomy. The other two rethromboses occurred in
patients who appeared to have intrinsic venous stenosis
after thrombolysis and underwent PTA. These rethrom-
boses were discovered at 8, 16, and 17 months after the
initial episode of SAVT. One of these patients was admit-
ted with an acute exacerbation of symptoms and under-
went successful thrombolysis and is awaiting rib resection.
Of the 12 patients who underwent PTA after thromboly-
sis, six underwent follow-up imaging studies, and two of
these patients were discovered to have rethrombosis. In
two patients SAVT developed on the other side. 
Two patients are known to have had thoracic outlet
decompression. One patient had transaxillary resection of
the first rib 3 months after her episode of SAVT. Another
patient underwent claviculectomy and subclavian vein
venolysis 4 months after being diagnosed. The claviculec-
tomy was performed because there was a remote history of
clavicular fracture on that side. One patient is awaiting first
rib resection. 
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Twenty-one of 28 patients were successfully contacted
for follow-up and completed the DASH questionnaire.
These patients responded from 2 months to 8 years after
their episode of SAVT (mean follow-up length of 2.9
years, median follow-up length of 1.6 years). Among these
21 patients were the two who had undergone decompres-
sive surgery and two patients who had chronically
occluded veins at initial diagnosis and did not undergo
surgery. Figs 2, 3, and 4 are graphical depictions of
patients’ DASH scores for the function/symptom compo-
nent, sports/music component, and the disability at work
component, respectively. We defined a DASH score of less
than 20 on the function/symptom score as indicative of
mild symptoms only, and 19 of 21 patients fell into the
category of mild or no symptoms. The mean score on the
function/symptom component of the DASH was 8.3.
The two patients who had undergone surgery had scores
of 12.5 and 65 on this component of the DASH. Four of
these patients were known to have occluded veins either
after attempted thrombolysis at initial assessment for
SAVT or on follow-up examinations, and the mean func-
tion/symptom score of these patients was 9.0.
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Figs 3 and 4 depict the respondents’ scores on the
sports/music and work components of the DASH. Most
patients (16 of 20) report no disability at work, and one
patient has had to change his occupation as a result of dif-
ficulty at the workplace. Of the 20 employed respondents,
five are manual laborers with occupations that involve
strenuous upper arm activity. Three of the laborers report
no symptoms, one (a butcher) reports some disability, and
one patient has had to change his occupation (a forester).
Fifteen of 21 patients report no disability with their
favorite musical/sporting activity. Six of 21 report mild to
severe disability in this category, and one patient has com-
pletely given up his favorite sporting activity. This patient
was an avid rower. None of the patients are high-level
competitive athletes.
DISCUSSION
Treatment for primary SAVT has evolved considerably
since the introduction of thrombolytic therapy. Older
studies studying the long-term outcome of patients
treated with anticoagulation alone showed poor outcome,
with most patients having persisting symptoms as a result
Fig 1. Results of diagnostic venography and thrombolysis. SAVT, Subclavian-axillary vein thrombosis.
Fig 2. Results of function/symptom component of DASH questionnaire.
of inadequate venous drainage of the arm.13,14 However,
the prognosis for these patients may be better than previ-
ously reported, and, in a more recent study consisting of
54 patients treated in such a manner, severe residual symp-
toms affected only 10% of patients.15 With the use of
thrombolytic therapy as initial treatment, most patients
will have marked immediate improvement of symptoms
after an episode of SAVT.3,16 Wilson et al16 reported on
eight patients with primary SAVT who were treated with
thrombolysis without rib resection. Seven of these eight
patients were completely symptom free up to 5 years after
initial therapy. However, having successfully recanalized
the axillary-subclavian vein segment with thrombolytic
treatments, one can recognize areas of venous stenosis and
extrinsic compression at the thoracic outlet that may have
predisposed to the episode of thrombosis. Surgical decom-
pression of the thoracic outlet at varying intervals after
thrombolysis appears to be gaining favor as the preferred
method of dealing with this condition in the hope of
maintaining venous patency and preventing rethrombo-
sis.1,5-8 The use of provocative venography is often
emphasized to look for any evidence of extrinsic compres-
sion of the subclavian vein; if it is seen, surgery is usually
recommended.6 This treatment approach is based on the
assumptions that surgery reduces the risk of rethrombosis,
that there is a high degree of correlation between venous
patency and symptoms, and that the morbidity of first rib
resection is minimal.
This series is unusual in that most patients did not
undergo decompressive surgery. Being a retrospective study,
it is impossible to determine precisely the reasoning for
treatment decisions in individual patients. Offering surgery
on the basis of patients’ symptoms and disability as was 
done is subjective, and it is quite likely that the surgeons in
this study had a higher threshold for intervention and
surgery than others who treat this condition. Individual
patients’ perceptions of their disability and attitudes toward
surgery also influence decision making. Importantly, the 
fact that all patients were initially able to return to their 
former employment likely contributed to the low interven-
tion rate. Although some of the patients were active athletes,
none of these patients were competitive athletes at high 
levels who might have been more sensitive to even minimal
degrees of disability and consequently seek more aggressive
treatment. 
At first glance the functional outcome as represented
by the patients responses on the DASH questionnaire
does not appear to be as favorable as those seen in other
recent series.4,7,8 Only six (28%) of 21 patients were
totally symptom free (none of these patients had under-
gone surgery). However, 13 of 21 had scores less than 20.
They all had relatively mild symptoms, and ultimately one
patient has had to change his occupation. The only symp-
toms that five of these patients reported as being present
were those of tingling or numbness in the hands and dis-
comfort with keeping the arms overhead. Many of these
symptoms may in fact reflect neurogenic thoracic outlet
syndrome rather than symptoms of venous obstruction.
The DASH is a detailed questionnaire and may be more
sensitive to very mild degrees of disability than asking
patients to globally rate the severity of symptoms as has
been done in other series.
Twenty percent of our patient population reported
some work-related disability, and one had to change his
work. This figure is similar to that seen in Machleder’s4
series of 50 patients, of which 36 underwent surgical decom-
pression. In that series, 10 of 50 patients had symptoms at
the workplace (20%), and six patients were disabled for their
usual occupations. Twenty-eight percent of our patients had
some disability with their favorite sporting/musical activity,
and one was unable to perform his favorite sporting activity.
It is important to note that none of our patients were or are
high-level competitive athletes. These patients are hampered
by even low levels of disability, and other series suggest that
these patients may seek and benefit from surgical treatment
more than other patients.4,17
The DASH questionnaire was developed by the
American Academy of Orthopedic surgeons and is in the
process of being validated for various upper extremity con-
ditions. To our knowledge, it has not been applied to any
neurovascular conditions of the upper extremity. This
must be kept in mind when evaluating the DASH scores
of our patients. It would be of interest to evaluate patients’
function and symptoms after a thoracic outlet decompres-
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Fig 3. Results of sports/music component of DASH question-
naire.
Fig 4. Results on work component of DASH questionnaire.
sion using the DASH questionnaire and compare those
results with that seen in our series.
In this series, three patients are known to have had
rethrombosis after initial thrombolysis. One patient had a
symptomatic, acute rethrombosis and underwent success-
ful thrombolysis. He is now awaiting first rib resection. Of
interest is the fact that he had moderate symptoms before
the episode of rethrombosis according to his score on the
DASH questionnaire. In retrospect, first rib resection
should perhaps have been done earlier in view of his per-
sisting symptoms. The second patient who had rethrom-
bosis did so after a claviculectomy. He had symptoms after
his episode of SAVT and a thoracic outlet decompression
was done. However, follow-up duplex scanning demon-
strated rethrombosis. At present, he has mild symptoms. A
third patient underwent follow-up duplex scanning as a
routine follow-up and was found to have had rethrombo-
sis. However, he is symptom free and no further interven-
tion was done. 
The three episodes of rethrombosis were discovered in
11 patients who underwent imaging (27%). This rethrom-
bosis rate is higher than those being reported in other
series where most patients undergo surgery.7,8,17 It is quite
possible that other patients in our group also have had
rethrombosis or have persisting severe stenoses. However,
our results on the DASH questionnaire indicate that those
with venous occlusion do not necessarily have severe symp-
toms. Four of our respondents to the DASH were known
to have occluded veins. Their mean score on the func-
tion/symptom component of the DASH was 9, and this
value is similar to the mean score of 8.3 for all 21 respon-
dents on this part of the questionnaire. Heron et al15 have
documented that the severity of late symptoms may not
correlate with the anatomic status of the vein as seen on
duplex scanning. In Dr Machleder’s series 64% of patients
with occluded veins were essentially free of symptoms.4
The risks of surgery to decompress the thoracic outlet
are relatively small but do include the possibility of
brachial plexus injury, Horner’s syndrome, injuries to the
long thoracic and phrenic nerves, as well as the possibility
of arterial, venous, and lymphatic injuries.18 Even after an
uncomplicated rib resection, patients who were previously
performing very strenuous activities may not be able to
resume them.19 The decision to proceed with thoracic
outlet decompression is thus a balance of these risks
against the potential of persisting symptoms or rethrom-
bosis without surgery. 
Many patients without axillary vein thrombosis can
appear to have venous obstruction with provocative
maneuvers. Matsumara et al20 studied 10 patients with
computed tomography scanning and found that they all
had compression of the subclavian vein with provocative
maneuvers. Rarely what appears to be primary SAVT may
in fact be the presentation of a hypercoagulable syn-
drome.15,21,22 Eight of 54 patients in the study by Heron
et al15 were discovered to have hypercoagulable states. It
may be important to consider these factors when recom-
mending surgery for patients with primary SAVT who
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appear to have extrinsic compression of the subclavian vein
with provocative maneuvers without intrinsic stenoses at
the thoracic outlet. Other authors have emphasized look-
ing for evidence of compression of the collateral vessels, as
well as the main vein with provocative maneuvers.17
Two of 21 patients with long-term follow-up had
development of SAVT on the other side (10%). The
reported incidence of bilateral SAVT ranges from 2% to
15%.1 In Machleder’s4 series more than half of the patients
with primary SAVT had venographic abnormalities on the
other side. However, thromboses develop on the other
side in only a small number of patients, and prophylactic
treatment of the other side seems unwarranted.
It is generally believed that patients with primary SAVT
should not undergo PTA because it is unlikely to improve
luminal caliber when extrinsic compression exists, and
there is concern that PTA in this setting may predispose to
rethrombosis.6 Twelve patients (48% of those with success-
ful thrombolysis) underwent PTA. Six of 12 patients in fact
had minimal or no improvement during the procedure
itself. It may be that PTA will be beneficial in a very small
number of these patients who do not have significant
extrinsic compression on the vein. Fortunately, we did not
note any immediate clinical deterioration or rethrombosis
in these patients as a result of the PTA. However, our expe-
rience with PTA before thoracic outlet decompression is
unusual, and more definitive comments on the effects of
PTA in our study cannot be made without more follow-up
imaging studies. Two of the late rethromboses were noted
in patients having undergone PTA, and the PTA may have
in some way contributed to rethrombosis. 
There has never been a direct comparison of patients
treated with or without thoracic outlet surgery after
thrombolysis for this condition. A prospective, random-
ized trial would be the ideal way to establish that thoracic
outlet decompression does improve long-term outcome.
This would indeed be difficult to do given the relative rar-
ity of this condition and would require multicenter coop-
eration for meaningful results to emerge. In the
meantime, much of the debate on this topic will consist of
comparing various series from different institutions.
Ultimately, the most important measure of treatment suc-
cess is the patient’s functional outcome. Use of standard-
ized outcome evaluation tools such as the DASH will
make results easier to interpret and facilitate comparison
between different series. 
Patients with primary SAVT are generally young,
healthy, and active. The follow-up period in our series was
on average 2.9 years, and for more definitive conclusions
to be drawn, one undoubtedly needs a longer follow-up
period. Another weakness in this series is that long-term
follow-up was only obtained on 75% of patients (21 of
28). This induces the potential for significant bias, and our
conclusions would be quite different if most of the seven
patients who did not respond to the questionnaire had
adverse outcomes. It is impossible to rule out the possibil-
ity that this group did indeed have a high incidence of
adverse outcomes. However, five of these seven patients
were seen in follow-up visits 2 to 5 months after their
episode of SAVT, at which time none of the five had any
symptoms. None of the seven patients were seen at any
interval after 5 months. If the nonrespondents had good
outcomes (mild or no symptoms), this would not affect
our present interpretation of the data.
In conclusion, on the basis of this series of patients, we
believe that anticoagulation and a nonoperative approach
after initial thrombolysis is appropriate. Treatment for this
condition should be individualized, and patients who have
symptoms that impair them at work or with activities that
are important to them should then be offered surgical
decompression. However, many patients have few or no
symptoms and will function well without surgery.
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CORRECTION
There is an error in the abstract “Prevention of pulmonary embolism and deep vein thrombosis with low dose
aspirin: Pulmonary Embolism Prevention (PEP) trial (Pulmonary Embolism Prevention [PEP] Trial Collaborative
Group. Lancet 2000;355:1295-302) in the “Suggested Reading Abstracts” section of the February issue of the Journal
of Vascular Surgery. The last line of the abstract should read: “The authors conclude there is now good evidence for
considering aspirin routinely in a wide range of surgical and medical patients.” It currently reads “no good evidence.”
